Hyperaldosteronism / Conn's syndrome

Hyperaldosteronism, also known as Conn's syndrome, is an increasingly recognized endocrine disorder in cats characterized by excessive production of the hormone aldosterone by the adrenal glands. This condition causes significant disturbances in electrolyte balance, most notably severe potassium depletion, along with systemic hypertension that can damage vital organs. Once considered rare in feline medicine, hyperaldosteronism has become more frequently diagnosed as awareness of the condition has grown and diagnostic capabilities have improved. The disorder typically affects middle-aged to older cats and can cause profound weakness and other serious clinical signs that significantly impact quality of life without appropriate treatment.

The underlying mechanism of hyperaldosteronism involves the adrenal cortex producing excessive aldosterone, the primary mineralocorticoid hormone responsible for regulating sodium and potassium balance in the body. Under normal circumstances, aldosterone acts on the kidneys to promote sodium retention and potassium excretion, helping maintain proper fluid balance and blood pressure. When aldosterone production becomes pathologically elevated, typically due to an adrenal tumor, the kidneys retain excessive sodium and water while excreting inappropriately large amounts of potassium. This creates a state of hypokalemia, or low blood potassium, which profoundly affects muscle and nerve function throughout the body. Simultaneously, the sodium and water retention drives blood pressure upward, causing hypertension.

The impact of hyperaldosteronism on affected cats manifests primarily through the consequences of severe hypokalemia and hypertension. Potassium depletion causes generalized muscle weakness that can progress to the point where cats cannot support their own body weight, creating a characteristic ventroflexion of the neck where the head drops downward. This weakness may extend to muscles throughout the body, affecting mobility and normal daily activities. Concurrent hypertension damages target organs including the eyes, heart, kidneys, and brain. Retinal changes from hypertension can cause sudden blindness. Cardiac effects include left ventricular hypertrophy as the heart works against elevated blood pressure. Kidney damage from chronic hypertension may compound any concurrent renal disease common in older cats.

Despite its serious effects, hyperaldosteronism is treatable when properly diagnosed. Surgical removal of adrenal tumors causing the condition offers the best chance of cure and is the treatment of choice when tumors are unilateral and resectable. For cats that are not surgical candidates, medical management can effectively control the condition through medications that block aldosterone's effects and potassium supplementation to correct deficiencies. Early recognition and treatment prevent progression of organ damage and restore quality of life for affected cats. The growing awareness of this condition among veterinarians means that more cats are being diagnosed earlier in the disease course when treatment is most effective, improving overall outcomes for this once under-recognized disorder.

The primary cause of hyperaldosteronism in cats is autonomous overproduction of aldosterone by one or both adrenal glands, typically resulting from neoplastic transformation of the adrenal cortex. Adrenocortical adenomas, which are benign tumors, account for approximately half of cases, while adrenocortical carcinomas, which are malignant, cause the remaining cases. These tumors arise from the zona glomerulosa, the outer layer of the adrenal cortex normally responsible for aldosterone production under tight physiological control. Tumor cells escape normal regulatory mechanisms and produce aldosterone continuously regardless of the body's actual needs, leading to chronic hormone excess. Less commonly, bilateral adrenal hyperplasia can cause similar hormone overproduction without discrete tumor formation.

Genetic and hereditary factors have not been established for feline hyperaldosteronism based on current evidence. Unlike some feline endocrine disorders with recognized breed associations, primary aldosteronism appears to occur sporadically without clear inheritance patterns. No specific gene mutations have been identified predisposing cats to adrenocortical tumor development. The condition occurs across all breeds without consistent overrepresentation in particular populations. This lack of identified genetic factors distinguishes feline hyperaldosteronism from some forms of human hyperaldosteronism where familial patterns have been documented. Future research may reveal genetic predispositions not yet recognized, but currently the condition is treated as a sporadic occurrence.

Environmental and lifestyle factors have not been linked to the development of hyperaldosteronism in cats. Unlike some conditions influenced by diet, toxin exposure, or living conditions, adrenal tumors causing aldosterone excess appear to arise without identifiable environmental triggers. Indoor versus outdoor lifestyle, dietary factors, and exposure to environmental chemicals have not been associated with increased risk. Chronic stress and its effects on adrenal function do not appear to predispose to tumor development. The spontaneous nature of tumor development in individual cats without clear external causes limits opportunities for environmental prevention strategies.

Risk factors for hyperaldosteronism primarily involve demographic characteristics rather than modifiable exposures. Age represents the most significant risk factor, with the majority of cases diagnosed in cats over ten years old, consistent with the general pattern of neoplastic disease increasing with advancing age. No clear sex predilection has been established, though some case series have reported slight female predominance. Concurrent chronic kidney disease is commonly present, though whether this represents a risk factor or consequence remains unclear. The presence of hypertension from any cause may prompt diagnostic testing that leads to hyperaldosteronism detection. Overall, the condition appears to develop spontaneously in aging cats without strongly predictive risk factors.

At the physiological level, hyperaldosteronism develops through progressive expansion of autonomous aldosterone-producing tissue within the adrenal gland. Neoplastic cells continue proliferating while producing aldosterone independent of the renin-angiotensin-aldosterone system that normally regulates production. The chronic aldosterone excess causes sustained activation of mineralocorticoid receptors in target tissues, particularly the kidneys. In renal tubular cells, this drives continuous sodium reabsorption and potassium secretion, depleting body potassium stores over time. The sodium retention expands extracellular fluid volume and increases blood pressure. Progressive potassium depletion eventually impairs muscle cell function when serum levels drop below the threshold required for normal membrane potential and contractile function, producing the characteristic weakness.

Early warning signs of hyperaldosteronism in cats often develop insidiously before dramatic symptoms appear. Owners may notice subtle changes in muscle strength, such as slightly decreased jumping ability or reluctance to climb. Mild lethargy or reduced activity levels may precede more obvious weakness. Some cats display intermittent symptoms that come and go, making early recognition challenging. Increased thirst and urination may develop as kidney function becomes affected. Occasional stumbling or unsteadiness might be attributed to aging rather than disease. Changes in vision behavior potentially indicating early hypertensive retinopathy, such as hesitation in unfamiliar environments or difficulty navigating in dim light, may go unnoticed. The gradual progression and nonspecific early symptoms frequently delay diagnosis until more severe manifestations develop.

Common symptoms of established hyperaldosteronism present a recognizable clinical picture centered on muscle weakness and hypertensive complications. The hallmark sign is profound generalized weakness, often dramatically manifesting as ventroflexion of the neck where the cat cannot lift its head normally. This neck weakness results from severe hypokalemia affecting the muscles supporting the head. Weakness affects all muscle groups, causing difficulty walking, reluctance to jump, and general immobility. Some cats cannot stand or support their body weight during severe episodes. Concurrent hypertension may cause acute blindness from retinal detachment or hemorrhage, often prompting emergency veterinary visits. Other cats present with nonspecific signs including weight loss, poor appetite, and general malaise reflecting the metabolic disturbance.

Behavioral changes accompanying hyperaldosteronism reflect both physical limitations and systemic illness effects. Affected cats typically become increasingly sedentary, resting more and avoiding activities requiring physical effort. Appetite may decrease as cats feel generally unwell. Social interactions often diminish with withdrawal from family activities. Some cats become more vocal, potentially expressing discomfort or distress. Changes in litter box habits may occur, with cats eliminating outside the box if weakness impairs their ability to climb in or maintain posture. Grooming behavior frequently decreases, leading to coat deterioration. The behavioral picture suggests a cat experiencing significant discomfort and physical limitation.

Physical signs observable during examination reveal the extent of electrolyte and blood pressure disturbances. Ventroflexion of the neck, when present, is immediately striking and nearly pathognomonic for severe hypokalemia in cats. Generalized muscle weakness is apparent during neurological assessment, with decreased strength, absent or reduced reflexes, and sometimes a stiff, stilted gait from polymyopathy. Blood pressure measurement typically reveals significant hypertension, often with systolic pressures exceeding 180 millimeters of mercury. Fundic examination may reveal changes including retinal hemorrhage, detachment, or vascular tortuosity indicating hypertensive ocular damage. Cardiac auscultation may detect heart murmurs or arrhythmias. Body condition often reflects chronic illness with muscle wasting. Palpation may rarely detect enlarged adrenal glands in thin cats.

Symptom progression in hyperaldosteronism follows a pattern of gradual worsening punctuated by acute crises. Early mild weakness progressively intensifies as potassium depletion advances. Hypertension gradually damages target organs over time. Some cats experience relatively stable chronic disease while others have dramatic acute decompensations when potassium levels drop critically low. Acute blindness from hypertensive retinopathy may occur suddenly after chronic asymptomatic hypertension. Weakness episodes may initially be intermittent before becoming constant. Without treatment, the disease trajectory leads to increasing debilitation, organ damage, and declining quality of life. The rate of progression varies considerably between individual cats.

Emergency symptoms requiring immediate veterinary attention include any acute severe weakness, particularly inability to stand or support the head. Sudden blindness indicating acute retinal damage requires urgent assessment even if the cat otherwise appears stable. Collapse or acute deterioration in a cat with known or suspected hyperaldosteronism needs emergency evaluation. Respiratory difficulty from severe muscle weakness affecting breathing muscles constitutes a life-threatening emergency. Cardiac arrhythmias from hypokalemia may cause collapse or sudden death. Neurological changes including seizures or altered consciousness suggest critical complications. Any dramatic acute change in a cat with suspected adrenal disease warrants immediate emergency care rather than waiting for scheduled appointments.

Initial veterinary examination for suspected hyperaldosteronism combines thorough history taking with comprehensive physical assessment. The veterinarian inquires about symptom onset and progression, particularly regarding weakness patterns and any vision changes. Activity level changes, appetite, and litter box habits provide supporting information. Physical examination specifically assesses muscle strength, checking for the characteristic cervical ventroflexion and generalized weakness. Blood pressure measurement is essential, with readings typically revealing significant hypertension in affected cats. Fundic examination evaluates for hypertensive ocular changes. The combination of muscle weakness consistent with hypokalemia plus hypertension creates high suspicion for hyperaldosteronism and indicates need for specific diagnostic testing.

Diagnostic testing for hyperaldosteronism involves several components to confirm the diagnosis and characterize the underlying cause. Serum chemistry reveals characteristic electrolyte abnormalities, most importantly hypokalemia with potassium levels often severely depressed below normal range. Hypernatremia or normal-high sodium is also typical. Creatine kinase elevation from muscle damage frequently accompanies severe hypokalemia. Kidney values may be elevated from concurrent renal disease or hypertensive nephropathy. The definitive diagnostic test is serum aldosterone measurement, which shows elevation above normal range. The aldosterone-to-renin ratio may help distinguish primary from secondary aldosteronism. Abdominal imaging, particularly ultrasound, visualizes the adrenal glands to identify tumors. CT imaging provides more detailed assessment of tumor extent and may reveal metastatic disease from carcinomas.

Differential diagnosis for cats presenting with weakness and hypertension must consider other conditions producing similar findings. Hypokalemia has multiple causes beyond hyperaldosteronism including chronic kidney disease with excessive potassium loss, dietary insufficiency, diabetic ketoacidosis, and certain medications. Hypertension likewise has numerous causes including kidney disease, hyperthyroidism, and essential hypertension without identifiable underlying cause. The combination of both findings significantly narrows the differential list, but confirmation requires hormone measurement. Other adrenal tumors producing different hormones must be distinguished through appropriate testing. The concurrent presentation of hypokalemia and hypertension with adrenal mass on imaging strongly suggests hyperaldosteronism, though laboratory confirmation remains important.

Diagnosis confirmation integrates clinical findings, laboratory results, and imaging to establish the diagnosis with confidence. Elevated serum aldosterone in the context of hypokalemia and hypertension confirms excessive aldosterone production. Identification of an adrenal mass on imaging localizes the source of hormone excess. Determining whether the tumor is unilateral or bilateral and benign versus malignant guides treatment planning. Unilateral tumors with contralateral gland atrophy suggest primary aldosterone-producing adenoma or carcinoma amenable to surgical removal. Bilateral adrenal enlargement may indicate hyperplasia or bilateral tumors requiring different management. Staging evaluation to detect metastatic disease from potential carcinomas includes thoracic imaging. Complete diagnostic workup establishes both the diagnosis and information needed for appropriate treatment selection.

Emergency treatment for cats presenting in hyperaldosteronism crisis focuses on rapidly correcting life-threatening hypokalemia and managing severe hypertension. Intravenous potassium supplementation addresses critical deficiency, administered carefully with cardiac monitoring since overly rapid correction can cause dangerous cardiac arrhythmias. Intravenous fluids support hydration and facilitate potassium repletion. Antihypertensive medications bring dangerously elevated blood pressure under control to prevent further organ damage. Cats with acute blindness from hypertensive retinopathy require urgent blood pressure management, as some vision may be recoverable if pressure is controlled quickly. Supportive care including nutritional support and comfortable positioning stabilizes critically ill patients. Emergency management stabilizes the patient while definitive treatment is planned.

Medical management provides effective control of hyperaldosteronism for cats not undergoing surgery or as adjunct to surgical treatment. Spironolactone, an aldosterone receptor antagonist, blocks the effects of excess aldosterone on target tissues, helping normalize electrolytes and blood pressure. This medication is typically continued long-term and requires dose adjustment based on response. Potassium supplementation corrects deficiency and maintains normal levels, administered orally as potassium gluconate or potassium citrate. Antihypertensive medications, commonly amlodipine in cats, control blood pressure to prevent ongoing target organ damage. The combination of aldosterone blockade, potassium replacement, and blood pressure control effectively manages the condition, though it does not address the underlying tumor and requires lifelong continuation.

Surgical treatment through adrenalectomy offers the best opportunity for cure when hyperaldosteronism results from a unilateral adrenal tumor. Surgical removal of the affected gland eliminates the source of aldosterone excess. Preoperative stabilization with medical management optimizes the patient's condition for surgery. The surgical procedure requires careful technique given the adrenal glands' proximity to major blood vessels and other vital structures. Post-operative monitoring addresses potential complications including adrenal crisis if remaining adrenal function is insufficient. Following successful surgery, many cats no longer require medical management and experience normalization of potassium and blood pressure. Surgical success rates are generally good when performed by experienced surgeons on appropriate candidates.

Supportive care measures complement primary treatment and address the systemic effects of hormone excess. Blood pressure monitoring throughout treatment guides medication adjustments to achieve target levels. Electrocardiographic monitoring may be needed during potassium replacement to detect cardiac effects. Dietary modification to include potassium-rich foods may provide supplemental support though alone is insufficient to correct significant deficiency. Physical support and safe environment help weakened cats avoid injury. Monitoring for complications including hypertensive organ damage, cardiac effects of electrolyte disturbances, and treatment side effects ensures comprehensive care. Regular reassessment determines treatment adequacy and guides ongoing adjustments.

Alternative and complementary approaches play limited roles in managing hyperaldosteronism, as the serious nature of the condition requires conventional medical or surgical intervention. Nutritional support through high-quality diets helps maintain overall health during treatment. Stress reduction through environmental modification may provide modest adjunctive benefit. No alternative treatments effectively control aldosterone excess or replace the need for conventional management. Complementary approaches should support rather than replace evidence-based treatment. The primary focus remains on aldosterone blockade, potassium management, and blood pressure control through proven medical means, with surgical cure when appropriate.

Treatment decisions incorporate multiple factors affecting optimal approach selection. Tumor characteristics including size, location, and suspected malignancy influence surgical candidacy. The cat's overall health status and ability to tolerate anesthesia and surgery factor into surgical recommendations. Medical management effectiveness must be weighed against surgical cure potential. Owner factors including financial resources for surgery or ongoing medical management, ability to administer long-term medications, and preferences regarding invasive procedures inform shared decision-making. Specialist referral may be recommended for surgical cases to optimize outcomes. Honest prognostic discussions help owners make informed choices aligned with their values and the cat's best interests.

Recovery timeline following treatment for hyperaldosteronism depends on the treatment approach and degree of organ damage present at diagnosis. Cats undergoing successful adrenalectomy typically show rapid improvement in potassium levels and muscle strength within days of surgery, with most cats regaining normal function within two to four weeks. Medical management produces more gradual improvement, with electrolyte normalization over days to weeks and progressive strength recovery following. Blood pressure typically responds to treatment within days, though reversal of hypertensive organ damage varies. Retinal damage may partially recover if treated promptly but established changes may be permanent. Cardiac remodeling from chronic hypertension improves gradually over months. Overall recovery depends significantly on disease severity and duration before treatment.

Post-treatment care requirements differ based on treatment modality. Following surgery, short-term monitoring ensures adequate remaining adrenal function and detects complications. Some cats require temporary glucocorticoid supplementation until the remaining adrenal gland recovers from suppression. Surgical site monitoring ensures proper healing. For medically managed cats, ongoing medication administration continues indefinitely. Regular monitoring of electrolytes ensures potassium remains within normal range with current supplementation. Blood pressure monitoring confirms adequate hypertension control. Periodic reassessment of medication doses optimizes management. Both surgical and medical patients require ongoing veterinary supervision, though intensity decreases as stability is achieved.

Prognosis factors influencing outcomes include tumor type, completeness of surgical removal, presence of metastatic disease, and extent of end-organ damage at diagnosis. Benign adenomas carry excellent prognosis when surgically removed, with cure expected in most cases. Carcinomas have more variable prognosis depending on tumor biology and whether complete excision is achieved. Metastatic disease significantly worsens outlook. Pre-existing hypertensive organ damage may be irreversible regardless of successful treatment of the underlying cause. Concurrent chronic kidney disease affects overall survival and may progress independently. Response to medical management in non-surgical cases provides prognostic information about long-term control feasibility.

Long-term outlook for cats with hyperaldosteronism is generally favorable when the condition is appropriately treated. Surgical cure provides the best long-term prognosis, with many cats returning to normal health and life expectancy. Medical management can effectively control the condition for years when surgery is not performed, allowing good quality of life with ongoing treatment. Regular monitoring enables detection of treatment failure or disease progression. The main threats to long-term outlook include carcinoma behavior including potential metastasis and progression, permanent hypertensive organ damage, and complications of chronic disease. With appropriate management, many cats live comfortably for years following diagnosis.

Primary prevention of hyperaldosteronism is not currently possible given the lack of identified preventable risk factors for adrenal tumor development. The spontaneous nature of neoplastic transformation in adrenocortical cells occurs without known environmental triggers or genetic predispositions that could be modified. General health maintenance through appropriate nutrition, regular veterinary care, and healthy lifestyle supports overall wellbeing but cannot specifically prevent adrenal tumor formation. Research into adrenal tumor development may eventually identify preventive opportunities, but no strategies exist based on current knowledge. Prevention efforts must instead focus on secondary prevention through early detection.

Environmental factors have not been linked to hyperaldosteronism development, limiting environmental prevention opportunities. Unlike some conditions with clear environmental triggers, adrenal tumors appear to arise spontaneously without identifiable external causes. Creating healthy living environments supports general feline health but cannot specifically prevent this condition. Reducing stress, providing appropriate nutrition, and maintaining regular veterinary care represent general wellness measures rather than targeted prevention. The absence of modifiable environmental risk factors means prevention strategies cannot target specific exposures.

Dietary approaches provide no known specific prevention against hyperaldosteronism development. Adequate potassium in the diet supports normal electrolyte balance but does not prevent tumor formation. High-quality nutrition maintains overall health without specific protective effects against adrenal neoplasia. For cats already diagnosed with the condition, appropriate dietary management supports medical treatment but does not represent primary prevention. The lack of dietary risk factors limits nutritional prevention opportunities.

Health maintenance through regular veterinary care enables early detection when prevention is not possible. Annual wellness examinations in middle-aged and older cats may detect subtle abnormalities suggesting developing disease. Routine blood pressure screening, increasingly recommended for senior cats, can identify hypertension prompting further evaluation. Blood work revealing unexplained hypokalemia triggers investigation that may lead to diagnosis. Building relationships with veterinary teams familiar with individual cats' baseline values facilitates recognition of changes. Early detection represents the most practical approach to reducing disease impact when true prevention remains elusive.

Early intervention when symptoms develop minimizes organ damage and improves outcomes. Recognizing warning signs including muscle weakness, vision changes, or nonspecific illness in older cats prompts timely veterinary evaluation. Investigating symptoms rather than attributing them to aging enables earlier diagnosis. Beginning treatment while disease is less advanced prevents progression of hypertensive end-organ damage. Prompt blood pressure control may preserve vision when acute hypertensive retinopathy occurs. The time-sensitive nature of some complications emphasizes the importance of seeking veterinary care without delay when concerning symptoms appear.

Daily management for cats living with hyperaldosteronism requires consistent attention to medication administration and monitoring. Cats on medical management receive multiple medications including spironolactone, potassium supplements, and typically amlodipine for blood pressure control. Administering medications at consistent times daily maintains stable drug levels. Potassium supplements are usually given divided into multiple daily doses for optimal effect. Monitoring appetite and food intake helps detect changes potentially indicating treatment problems. Water consumption tracking provides information about hydration status. Daily observation for weakness, vision changes, or other symptoms catches emerging problems early. Maintaining detailed medication and observation logs supports effective veterinary communication.

Home environment modifications support cats recovering from or living with hyperaldosteronism-related weakness. Providing easily accessible food and water eliminates the need for climbing or jumping. Low-sided litter boxes allow entry without requiring physical effort. Soft, padded bedding in accessible locations provides comfortable resting options. Removing obstacles creates clear pathways for unsteady movement. Non-slip surfaces help cats with residual weakness maintain traction. Keeping essentials on a single level eliminates stair navigation when possible. Creating calm, quiet spaces allows rest and recovery. These modifications support safety and comfort during the treatment period and beyond.

Maintaining quality of life focuses on comfort and contentment while managing chronic disease. Despite the diagnosis, many cats enjoy excellent quality of life once treatment achieves disease control. Gentle interaction and affection maintain emotional bonds without causing physical stress. Appropriate play at the cat's activity level provides enrichment. Comfortable resting in favorite locations supports wellbeing. Regular grooming assistance maintains coat condition if self-grooming decreases. Appetite stimulation helps if eating declines. Quality of life assessment considers whether the cat experiences more good days than bad and maintains activities bringing enjoyment. Treatment goals prioritize comfort and happiness alongside medical parameters.

Ongoing monitoring ensures continued treatment effectiveness and catches complications early. Regular veterinary rechecks assess clinical status through examination, blood pressure measurement, and laboratory testing. Electrolyte monitoring confirms potassium remains within normal range. Blood pressure assessment verifies adequate hypertension control. Periodic reassessment of adrenal imaging may be recommended for carcinoma cases to monitor for progression or metastasis. Between appointments, owners watch for weakness, vision changes, appetite decline, or behavioral changes warranting earlier consultation. The monitoring intensity adjusts based on disease stability, with more frequent assessment during dose adjustments and less frequent maintenance monitoring once stable.

Caregiver support resources help owners manage the ongoing demands of chronic disease management. Veterinary teams provide guidance, answer questions, and offer emotional support through challenging periods. Clear communication about treatment goals and prognosis helps owners maintain realistic expectations. Financial planning addresses ongoing medication and monitoring costs. Respite arrangements through trusted pet sitters familiar with medication routines allow needed breaks. Online resources and communities may connect owners facing similar challenges. Recognizing caregiver fatigue and seeking support when needed sustains both owner wellbeing and quality of care. The manageable nature of well-controlled hyperaldosteronism with modern treatment allows many cats and owners to adapt successfully to long-term disease management.

High-risk breeds for hyperaldosteronism have not been identified in cats based on available evidence. Unlike some feline endocrine disorders with established breed associations, primary aldosteronism appears to occur without breed predilection. Published case series and reports include cats of various breeds without consistent overrepresentation of specific populations. Domestic shorthair and domestic longhair cats comprise the majority of reported cases, reflecting their predominance in the general cat population rather than increased susceptibility. The absence of breed predispositions suggests that tumor development occurs sporadically based on individual factors rather than inherited genetic susceptibility. This pattern differs from some human forms of hyperaldosteronism with familial clustering.

Moderate-risk categories based on demographic factors rather than breed have been characterized in published literature. Middle-aged to older cats face the highest risk, with most cases diagnosed in cats over ten years of age, consistent with the general age-related increase in neoplastic disease. Some reports suggest slight female predominance, though this finding is not consistent across all studies. No size, body type, or coat characteristics have been associated with increased risk. Cats with concurrent chronic kidney disease commonly have hyperaldosteronism, though the causal relationship remains unclear. Overall, the demographic profile suggests an aging-related condition occurring across the feline population without strong predictive factors.

Screening recommendations cannot target specific breeds given the absence of breed associations. General wellness screening for older cats provides the best opportunity for early detection. Annual or twice-yearly blood pressure measurement in cats over seven to ten years identifies hypertension requiring investigation. Routine blood work revealing unexplained hypokalemia prompts further evaluation. Owner awareness of symptoms including weakness, vision changes, and behavioral alterations supports timely presentation for evaluation. The nonspecific nature of early symptoms makes screening through routine veterinary care particularly valuable. When clinical suspicion arises, appropriate diagnostic testing including aldosterone measurement and adrenal imaging enables definitive diagnosis.

Commonly co-occurring conditions with hyperaldosteronism share related pathophysiology or occur in the same patient population. Chronic kidney disease frequently coexists, present in a substantial proportion of affected cats. Whether this represents shared risk factors, consequences of chronic hypertension, or coincidental occurrence in the aging cat population remains incompletely understood. Hypertensive retinopathy develops from the sustained elevated blood pressure, causing retinal changes ranging from vascular abnormalities to hemorrhage and detachment with vision loss. Cardiac disease including left ventricular hypertrophy results from the heart working against chronically elevated blood pressure. These concurrent conditions require evaluation and management alongside the primary aldosteronism.

Conditions with similar symptoms require differentiation from hyperaldosteronism to ensure appropriate treatment. Other causes of hypokalemia include chronic kidney disease with urinary potassium wasting, diabetic ketoacidosis, dietary deficiency, and medication effects. Hypertension has numerous causes including renal disease, hyperthyroidism, and primary hypertension without identifiable underlying cause. Muscle weakness has many potential explanations beyond electrolyte disturbances. Other adrenal disorders including pheochromocytoma and hyperadrenocorticism may present with hypertension and systemic symptoms. Thorough diagnostic evaluation including hormone measurement distinguishes these conditions, as treatment approaches differ substantially.

Potential complications of hyperaldosteronism or its treatment require ongoing vigilance. Permanent vision loss from hypertensive retinopathy represents irreversible end-organ damage when treatment is delayed. Progressive cardiac changes from chronic hypertension may advance despite treatment. Kidney damage from hypertension compounds any concurrent renal disease. Adrenal carcinoma may metastasize, worsening prognosis significantly. Treatment complications include over-correction of potassium causing hyperkalemia, hypotension from antihypertensive therapy, and surgical complications for cats undergoing adrenalectomy. Monitoring throughout treatment enables early detection and management of complications, optimizing overall outcomes for affected cats.